PNV-001, also known as deuterated basmisanil, is a highly selective α5 subunit-containing GABAA receptor negative allosteric modulator which is under investigation for the treatment of treatment-resistant depression and suicidal ideation. It is a deuterated analogue of basmisanil with improved pharmacokinetics and metabolic stability. The drug's half-life is 5.5-fold longer than that of basmisanil in human liver microsomes in vitro. It produces rapid and persistent antidepressant-like effects in animals. PNV-001 and related drugs are said to lack the undesirable central effects of hallucinogens like ketamine and serotonergic psychedelics and of non-subunit-selective GABAA receptor negative allosteric modulators like flumazenil. It is being developed by ProNovo Therapeutics. As of September 2023, it is in the preclinical research stage of development.
See also GABAA receptor negative allosteric modulator List of investigational antidepressants L-655,708 and MRK-016
References
External links Pipeline - ProNovo Therapeutics
